Reaction

Cholangitis Sclerosing reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,036 reports · 42 co-occurring drugs

As of the last recalculation, Cholangitis Sclerosing appears in 2,036 FAERS reports alongside 42 co-occurring drug terms. The strongest observed disproportionality signal is URSOSIOL (PRR 50.0).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Ursosiol	91	50.0	50.3
Ursodiol	95	46.7	46.9
Vedolizumab	256	34.6	34.7
Doxyclycline Hyclate	37	22.6	22.7
Doxycycline Hyclate	135	21.8	21.9
Nivolumab	177	20.4	20.4
Doxycycline	126	20.1	20.1
Cholestyramine	23	19.7	19.7
Pembrolizumab	175	18.5	18.5
Mesalamine	91	17.3	17.3
Isotretinoin	78	16.7	16.7
Adalimumab-Fkjp	72	16.4	16.5
Dronedarone	16	16.2	16.2
Adalimumab-Aaty	68	15.2	15.2
Atezolizumab	55	14.9	14.9
Azathioprine	117	14.3	14.4
Adalimumab-Adaz	69	13.8	13.8
Infliximab	238	12.5	12.5
Durvalumab	22	11.2	11.2
Naltrexone Hydrochloride And Bupropion Hydrochloride	9	10.8	10.8
Paclitaxel (Aibumin-Bound)	81	10.4	10.5
Ipilimumab	43	10.4	10.4
Bicalutamide	15	10.1	10.1
Paclitaxel	94	10.1	10.1
Infliximab-Dyyb	27	9.6	9.6
Ustekinumab	88	9.1	9.1
Diphenoxylate Hydrochloride And Atropine Sulfate	12	9.0	9.0
Mercaptopurine	14	8.3	8.3
Carboplatin	97	8.1	8.2
Vemurafenib	9	7.7	7.7
Lenvatinib	23	7.2	7.2
Ceftriaxone	23	7.2	7.2
Pemetrexed Disodium	26	7.1	7.1
Ceftriaxone Sodium	24	6.5	6.5
Tofacitinib Citrate	8	6.3	6.3
Goserelin	8	6.1	6.1
Polatuzumab Vedotin	5	5.2	5.3
Bevacizumab	58	4.9	4.9
Encorafenib	4	4.1	4.1
Rifaximin	8	3.9	3.9
Abemaciclib	7	3.6	3.6
Guselkumab	6	1.7	1.7

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.